Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 19/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ASPH | Q12797 | 1/20 | 0.37 |
| ▸ | RIOX2 | Q8IUF8 | 1/20 | 0.37 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765487 | 0.91 | ELANE (0.41) | ELANE | |
| SCHEMBL30765958 | 0.89 | GAA (0.42) | ELANE | |
| SCHEMBL30766006 | 0.87 | KDM4E (0.42) | ELANEKDM4EASPHRIOX2KDM8 | |
| SCHEMBL30765652 | 0.86 | KDM4E (0.38) | ELANEKDM4EASPHRIOX2KDM8 | |
| SCHEMBL30766097 | 0.82 | ASPH (0.49) | ELANEKDM4EASPHRIOX2KDM8 | |
| SCHEMBL31558457 | 0.81 | KDM4E (0.41) | ELANEKDM4EASPHRIOX2KDM8 | |
| SCHEMBL30765739 | 0.79 | F2 (0.38) | ELANEKDM4EASPHRIOX2KDM8 | |
| SCHEMBL30766118 | 0.78 | ELANE (0.41) | ELANEKDM4EASPHRIOX2KDM8 | |
| SCHEMBL23461187 | 0.76 | KDM4E (0.47) | ELANEKDM4EASPHRIOX2KDM8 | |
| SCHEMBL30765630 | 0.76 | GAA (0.47) | ELANEKDM4EASPHRIOX2KDM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |